Prospective study shows Ga-HER2 PET/CT predicts pathologic response in HER2-positive breast cancer, suggesting early intervention benefits.
Ga-HER2 PET/CT uptake during NAT provide an effective early indicator of therapeutic sensitivity in HER2-positive breast cancer, supporting its value for predicting pathologic response at both early treatment and preoperative stages.
No takes yet. Share an insight, caveat, or question.
Gao et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: